ClinicalTrials.gg
RecruitingNCT07900893CNTRACSUpdated Nov 9, 2026

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3

An interventional study of Motion Perception Task and Sine Wave Speech Task in Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder) and Healthy Adult, sponsored by Washington University School of Medicine. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Basic science

Updated Oct 28, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
10,000
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Study summary

In Study 3, all tasks and models from Aim 1 will be evaluated in a large community sample of online participants recruited through Prolific.

Aim 3 will establish 1) requirements for testing computational algorithms in population-based samples, 2) whether task length is optimal, and 3) whether computational parameters help predict psychopathology (hallucinations and delusions in particular) in the general population, and how these predictors may be impacted by demographic variables, such as race, ethnicity, gender, age and other social determinants of health.

Participant demographics will be matched to the U.S. Census 2023 American Community Survey (ACS) data release (updated as available). MPI MacDonald has successfully recruited large online samples for over a decade.

Specifically, researchers will recruit two samples of n=2,000 to preregister hypotheses and then n=3,000 to independently confirm those hypotheses. Multiple methods will affirm the highest quality human self-report and behavioral data for online samples.

Researchers use Prolific, which is known for high quality research participation, maintaining low levels of bots through strategies such as requiring a photo ID and a waiting period. Second, inclusion criteria will require an approval rating of 90-100% from previous researchers. Participants will complete three sessions, each limited to \~60 min to avoid burnout.

Read the detailed description

Researchers will recruit two samples of 2,000 to preregister hypotheses and then 3,000 to independently confirm those hypotheses.

Multiple methods will affirm the highest quality human self-report and behavioral data for online samples. First, researchers will use Prolific, which is known for high quality research participation, maintaining low levels of bots through strategies such as requiring a photo ID and a waiting period. Participants will complete 3 sessions, each limited to \~60 min to avoid burnout. Researchers anticipate complete data from 74% of participants, based on data completion rates in the previous online study.

General Cognitive Ability. Researchers will include standard general cognitive measures to assess the specificity of effects beyond general cognitive impairment. Specifically, researchers will include validated online measures from TestMyBrain (https://www.testmybrain.org/using-tmb/research.html; Digit Symbol Coding, Vocabulary, and Matrix Reasoning), as in our prior work in both clinical and healthy populations.

Self-Report Questionnaires: Researchers will use the Beliefs about Voices Scale which assesses attributions about the origin and power of voices, and the Yale Control Over Perceptual Experiences (COPE) scale, which evaluates the extent to which people feel they can exert control over their voices. Researchers will also use the Peters Delusion Inventory to assess the extent of delusional thinking, supplemented by the Green Paranoia Scale, which provides additional coverage of persecutory beliefs. To assess specificity, researchers will use the Patient Health Questionnaire (PHQ-9) to assess depression, the Generalized Anxiety Disorder Scale (GAD-7)78 to assess anxiety, and the Motivation and Pleasure Scale-Self-Report (MAP-SR) to assess anhedonia and motivation with the addition of additional measures of psychosis (Aberrant Salience Inventory, Schizotypal Personality Questionnaire - Brief), alcohol use (AUDIT), cannabis use (Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory), and tobacco and other substance use (World Health Organization (WHO) Alcohol, Smoking and Substance Involvement Screening Test), as researchers will not have a Stuctured Clinical Interview (SCID) for on-line participants.

Researchers will also measure daily functioning using the World Health Organization Disability Assessment Schedule (WHODAS) 2.0. Validity questions and procedures will be included. These measures will take 30 mins to complete, as researchers found in prior studies. Researchers will conduct a principal components analysis (PCA) on measures of the same construct (e.g., delusions) and perform primary analyses using the first principal component, followed by secondary analyses of specific measures False Discovery Rate (FDR) correction.

02

Conditions studied

  • Schizophrenia / Schizoaffective Disorder
  • SCHIZOPHRENIA 1 (Disorder)
  • Healthy Adult

Keywords

  • schizophrenia
  • schizo-affective
  • healthy controls
03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,803 studies on the registry; 271 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Residents of the U.S.
  • between 18-59 years of age

Exclusion criteria

Exclusion Criteria:

  • Resides outside of U.S.
  • under 18 or over 59 years of age
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10,000 participants (estimated)

Interventions

  • BehavioralMotion Perception Task

    Assesses updating of beliefs from new sensory inputs with prior knowledge via perceiving direction changes in random dot motion stimuli

  • BehavioralSine Wave Speech Task

    Measures the degree to which overweighting of prior beliefs impacts processing of sensory inputs (detection of speech).

  • BehavioralVolatility Task

    Measures the updating of priors about the location of a bag drop from a helicopter when the location changes (prediction errors).

  • BehavioralChoice Probabilistic Reversal Task

    Assesses prior belief updating when feedback about obtaining positive outcomes changes (prediction errors).

  • BehavioralKamin Blocking Task

    Examines the role of mismatches between learned priors and new information (prediction errors) in belief formation about event causes.

  • BehavioralMinnesota Trust Game

    Assesses the degree to which people distinguish between their priors about others' motivations, such as selfishness and spite, and impersonal chance in one-shot trust game and dictator games.

  • BehavioralDynamic Trust Game

    Assesses degree to which people learn and update priors about trusting partners from dynamic social feedback (prediction error) in a social exchange game.

06

What researchers measure

Primary outcomes

  1. Motion Perception Task Performance

    With 15 degrees of initial or changed direction vs. the probability of failing to update

    Time frame: 1 hour

  2. Sine Wave Speech Task Performance

    Percentage of trials coded as speech or not vs Dprime

    Time frame: 1 hour

  3. Volatility Task Performance

    Percent correct bag captures during periods of stability vs. instability - patients worse in both, but particularly impaired ininstability vs. Environmental volatility belief parameter

    Time frame: 1 hour

  4. Choice Probabilistic Reversal Performance Task

    Win-switch rate (higher in patients, particularly paranoid patients) vs. (prior on volatility belief updating in response tovolatility

    Time frame: 1 hour

  5. Kamin Blocking Task Performance

    Number of times participant predict allergy following blocked cue vs. prediction errors and learning rates

    Time frame: 1 hour

  6. Minnesota Trust Game Performance

    Percent of trusting choices depending on decision-agent and temptation vs. spite-guilt beliefs estimate

    Time frame: 1 hour

  7. Dynamic Trust Game Performance

    Trust indexed by mean investment versus learning rates

    Time frame: 1 hour

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Hamid AA, Frank MJ, Moore CI. Wave-like dopamine dynamics as a mechanism for spatiotemporal credit assignment. Cell. 2021 May 13;184(10):2733-2749.e16. doi: 10.1016/j.cell.2021.03.046. Epub 2021 Apr 15. PubMed 33861952 ↗
  • Pratt DN, Barch DM, Carter CS, Gold JM, Ragland JD, Silverstein SM, MacDonald AW. Reliability and Replicability of Implicit and Explicit Reinforcement Learning Paradigms in People With Psychotic Disorders. Schizophr Bull. 2021 Apr 29;47(3):731-739. doi: 10.1093/schbul/sbaa165. PubMed 33914891 ↗
  • Liu RG, Frank MJ. Hierarchical clustering optimizes the tradeoff between compositionality and expressivity of task structures for flexible reinforcement learning. Artif Intell. 2022 Nov;312:103770. doi: 10.1016/j.artint.2022.103770. Epub 2022 Aug 5. PubMed 36711165 ↗
  • Kwashie AN, Ma Y, Barch DM, Chafee M, Ragland JD, Silverstein SM, Carter CS, Gold JM, MacDonald AW 3rd. Comparing the functional neuroanatomy of proactive and reactive control between patients with schizophrenia and healthy controls. Cogn Affect Behav Neurosci. 2023 Feb;23(1):203-215. doi: 10.3758/s13415-022-01036-6. Epub 2022 Nov 23. PubMed 36418846 ↗
  • Boudewyn MA, Erickson MA, Winsler K, Ragland JD, Yonelinas A, Frank M, Silverstein SM, Gold J, MacDonald AW 3rd, Carter CS, Barch DM, Luck SJ. Managing EEG studies: How to prepare and what to do once data collection has begun. Psychophysiology. 2023 Nov;60(11):e14365. doi: 10.1111/psyp.14365. Epub 2023 Jun 14. PubMed 37314113 ↗
  • Erickson MA, Boudewyn MA, Winsler K, Li C, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas A, Luck SJ. Dysfunctional Alpha Modulation as a Mechanism of Working Memory Impairment in Serious Mental Illness. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Dec;9(12):1271-1280. doi: 10.1016/j.bpsc.2024.07.022. Epub 2024 Aug 6. PubMed 39117276 ↗
  • MacDonald AW, Patzelt E, Kurth-Nelson Z, Barch DM, Carter CS, Gold JM, Ragland JD, Silverstein SM. Computational modeling of reversal learning impairments in schizophrenia and bipolar disorder reveals shared failure to exploit rewards. J Psychopathol Clin Sci. 2025 Apr;134(3):262-271. doi: 10.1037/abn0000944. Epub 2025 Mar 10. PubMed 40063391 ↗
  • Li C, Boudewyn MA, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas A, Luck SJ, Erickson MA. Impacted and preserved sub-domains of cognitive control in schizophrenia. Neuropsychologia. 2026 Sep 9;230:109503. doi: 10.1016/j.neuropsychologia.2026.109503. Epub 2026 May 25. PubMed 42184934 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Our plan is to share de-identified participant data through the National Data Archive (NDA) as required bythe National Institute of Mental Health (NIMH)

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2031, 54 months later.

Of 753 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 54 months is above that.

Counting every sponsor, half of 766 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Oct 28, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 30, 2031
CompletionEst.
Jun 30, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Minnesota · Minneapolis, United StatesContact z•••@umn.edu · •••1275→C•••@umn.edu · •••1275
Nov 9, 2026
Registered
First appeared on the registry
Oct 28, 2026
Show all 2 updates
  1. Nov 9, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Minnesota · Minneapolis, United StatesContact z•••@umn.edu · •••1275→C•••@umn.edu · •••1275
  2. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07900893
Responsible party
Deanna Barch (Professor of Psychological & Brain Sciences Professor of Radiology , Gregory B. Couch Professor ofPsychiatry, Washington University School of Medicine) — Principal investigator
First posted
Oct 28, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2031 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

Deanna Barch, PhD
Contact
dbarch@wustl.edu
314-935-8729
Deanna Barch, PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion